139042-59-4

Basic information

• Product Name: 1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE
• Synonyms: 3-ACETYL-6-BROMOPYRIDINE;1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE;2-BROMO-5-ACETYLPYRIDINE;5-acetyl-2-bromopyridine;1-(6-Bromopyrid-3-yl)ethan-1-one;5-Acetyl-2-bromopyridine 97%;1-(6-BROMOPYRID-3-YL)ETHANONE;1-(6-Bromopyridin-3-yl)ethan-1-one
• CAS NO: 139042-59-4
• Molecular Formula: C₇H₆BrNO
• Molecular Weight: 200.03
• EINECS: 625-249-8
• Product Categories: Pyridine;Heterocycle-Pyridine series
• Mol File: 139042-59-4.mol

Chemical Properties

• Melting Point: 124-128 °C(lit.)
• Boiling Point: 291.3 °C at 760 mmHg
• Flash Point: 130 °C
• Appearance: light yellow to dark yellow liquid
• Density: 1.534 g/cm³
• Vapor Pressure: 0.00196mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: soluble in Methanol
• PKA: -1.01±0.10(Predicted)
• CAS DataBase Reference: 1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE(139042-59-4)
• EPA Substance Registry System: 1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE(139042-59-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 139042-59-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of biologically active compounds. Its unique structure and reactivity allow for the creation of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE is utilized as a building block in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and weeds, thereby improving crop yields and quality.
Used in Drug Discovery:
1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE is employed as a valuable tool in drug discovery, where its unique properties and reactivity enable researchers to explore new chemical entities with potential therapeutic benefits. Its versatility in organic synthesis allows for the development of novel drug candidates with improved efficacy and safety profiles.
Used in Organic Synthesis:
As a versatile organic compound, 1-(6-BROMO-PYRIDIN-3-YL)-ETHANONE is used in organic synthesis to create a wide range of chemical products. Its reactivity and structural features make it an ideal starting material for the synthesis of various organic compounds, including complex molecules with specific applications in different industries.

InChI:InChI=1/C7H6BrNO/c1-5(10)6-2-3-9-7(8)4-6/h2-4H,1H3

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 127-19-5 N,N-dimethyl acetamide 
• 13534-97-9 6-bromopyridine-3-amine 
• 431-03-8 dimethylglyoxal 

Downstream Products

• 23092-75-3 1-(6-chloropyridin-3-yl)ethanol 
• 139163-63-6 (1S)-1-(6-bromopyridin-3-yl)ethanol 
• 139163-64-7 R-(6-bromopyridin-3-yl)ethanol 
• 871366-23-3 5-acetyl-2-pyridinecarboxaldehyde 
• 136592-20-6 2-bromo-1-(6-bromopyridin-3-yl)ethanone 
• 139042-62-9 1-(6-bromopyridin-3-yl)ethan-1-ol 
• 1048004-04-1 1-(6-(pyridin-3-yl)pyridin-3-yl)ethanone 
• 35022-79-8 1-(6-phenylpyridin-3-yl)ethan-1-one 
• 958456-33-2 (E)-1-(6-bromopyridin-3-yl)-3-(4-(dimethylamino)phenyl)prop-2-en-1-one 
• 1095275-20-9 1-(6-bromopyridin-3-yl)-3-(3,5-dichlorophenyl)-4,4,4-trifluoro-3-hydroxybutan-1-one 
• 1259929-69-5 1-(6-vinylpyridin-3-yl)ethanone 
• 477252-29-2 2-(6-bromopyridin-3-yl)propan-2-ol 
• 1613027-82-9 tert-butyl [2-(5-acetylpyridin-2-yl)phenyl]carbamate 
• 358780-14-0 1-[(6-trifluoromethyl)-pyridine-3-yl]ethan-1-one 

Relevant articles and documents

Photoinduced Acetylation of Anilines under Aqueous and Catalyst-Free Conditions

A green and efficient visible-light induced functionalization of anilines under mild conditions has been reported. Utilizing nontoxic, cost-effective, and water-soluble diacetyl as photosensitizer and acetylating reagent, and water as the solvent, a variety of anilines were converted into the corresponding aryl ketones, iodides, and bromides. With advantages of environmentally friendly conditions, simple operation, broad substrate scope, and functional group tolerance, this reaction represents a valuable method in organic synthesis.

NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1

An object of the invention is to provide compounds as selective JAK1 inhibitor, a process for preparation of the inhibitors, a composition containing the compounds and utility of the compounds.

RADIONUCLIDE-LABELED COMPOUND AND IMAGING AGENT CONTAINING THE SAME

PROBLEM TO BE SOLVED: To provide: a radionuclide-labeled compound having both tau protein affinity and amyloid protein affinity; an imaging agent that contains the radionuclide-labeled compound and that is used for imaging tau proteins and/or amyloid proteins; and a radioactive medicine that contains the radionuclide-labeled compound and that is used for diagnostic imaging of diseases caused by the aggregation of tau proteins and/or amyloid proteins. SOLUTION: The present invention provides radionuclide-labeled compounds represented by general formula (1) or salts thereof. (In the formula, X represents a radioactive iodine atom,18F or 11CH3; pyridine and oxazole are bound by a carbon atom; and pyridine is bound to imidazopyridine by a carbon atom.) SELECTED DRAWING: None COPYRIGHT: (C)2019,JPO&INPIT

NOVEL GPR119 AGONIST COMPOUNDS

The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect

A new series of N-substituted-2-aminopyrimidines based on the '4-(pyridin-3-yl)pyrimidin-2-amine' scaffold of Imatinib has been designed and synthesized. A selected group from the target compounds was tested over a panel of 60 cancer cell lines at a single dose concentration of 10 μM, and the two most active compounds, 25b and 30, were further tested in a five-dose testing mode to determine their IC50 values over the 60 cell lines. Compound 30 has showed good potencies and high efficacies, and was accordingly tested at a single dose concentration of 10 μM over a panel of 54 kinases. At this concentration, the compound has showed multiple inhibitions over a number of oncogenic kinases, including ABL1, AKT1, LCK, C-SRC, PIM1, FLT3, FYN, and KDR. A molecular modeling study was made by docking of the most active compound 30 and its inactive analog 29 into the kinase domain of ABL1 to investigate their possible binding interactions.

Synthesis of new N-arylpyrimidin-2-amine derivatives using a palladium catalyst

New N-aryl-4-(pyridin-3-yl)pyrimidin-2-amine derivatives were synthesized from the corresponding amines, applying optimized Buchwald-Hartwig amination conditions using dichlorobis(triphenylphosphine)Pd(II), xantphos and sodium tert-butoxide in refluxing toluene under a nitrogen atmosphere. The target N-aryl derivatives were obtained in moderate to good yields ranging from 27% to 82%. The procedure described could be widely employed for the preparation of new heterocyclic compounds. The structures of the new compounds were confirmed by FT-NMR, FT-IR and elemental analysis.

Preparation and antioxidant activity of α-pyridoin and its derivatives

Focusing on α-pyridoin (1, 1,2-di(2-pyridyl)-1,2-ethenediol) as the lead compound of the novel antioxidative enediol, we synthesized 5,5′- or 6,6′-bis-substituted derivatives of 1 from disubstituted pyridines. The antioxidant activity of 1 and its synthetic derivatives 2-7 was evaluated by DPPH (1,1-diphenyl-2-picrylhydrazyl radical) scavenging assay and inhibition of lipid peroxidation. In the DPPH assay, 1 exhibited an activity stronger than that of ascorbic acid, and 5,5′-dimethyl-(5) or 5,5′-dimethoxy- substituted derivatives (6) exhibited more potent activity than 1. The DPPH scavenging activities of α-pyridoins were correlated with their oxidation potential and thus the electron density of enediol. 5 and 6 effectively inhibited lipid peroxidation in the rat liver microsome/tert-butyl hydroperoxide system. Therefore, 5 and 6 serve as good candidates for a pharmacologically useful enediol antioxidant.

OXIME DERIVATIVES

The invention concerns oxime derivatives of the formula I wherein R4 includes hydrogen, carboxy, carbamoyl, amino, cyano, trifluoromethyl, (1-4C)alkylamino, di(1-4C)alkylamino and (1-4C)alkyl; RS includes hydrogen, (1-4C)alkyl, (3-4C)alkeny1,(3-4C)alkynyl, (2-5C)alkanoyl, halogeno-(2-4-C)alkyl and hydroxy-(2-4C)alky1;Arl is phenylene or a hetercaryl diradical; Al is a direct link to XI, or Al is (1-4C)alkylene; XI is oxy, thio, sulphinyl or sulphonyl; Ar2 is phenylene or a heteroaryl diradical; RI is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkyny1; and R2 and R3 together form a group of the formula -A2. X2-A3- which together with the carbon atom to which A2 and A3 are attached define a ring having 5 or 6 ring atoms, wherein each of A2 and A3 is (1-3C)alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable sah thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

Enantioselective Synthesis of Optically Active Pyridine Derivatives and C2-Symmetric 2,2'-Bipyridines

Optically active pyridine derivatives 2, 15, 18, 19, 21, 26, and 27 are obtained by enantioselective reduction of the corresponding ketones 5, 7, 11-13, 24, and 25 using the chiral borane reagent chlorodiisopinocampherylborane .Nickel(0)-mediated coupling of bromopyridines 2, 15, and 31 gives C2-symmetric 2,2'-bipyridines (R,R)-32, (R,R)-33, and (S,S)-38, respectively, which form metal complexex with Co(II), Pd(II), Cu(I), and Ag(I).Aryl-substituted pyridines 26, and 39-41 are synthesized by palladium(0)-catalized cross coupling of 2 and 15 with boronic acids 42-44.Key Words: 2,2-Bipyridines / Pyridines, optically active / Chiral ligands / Asymmetric Synthesis / Catalysis, enantioselective